Acute Heart Failure Is a Malignant Process: But We Can Induce Remission

Author:

Cotter Gad123ORCID,Davison Beth A.123,Lam Carolyn S. P.45,Metra Marco6,Ponikowski Piotr7ORCID,Teerlink John R.8,Mebazaa Alexandre39ORCID

Affiliation:

1. Heart Initiative Durham NC

2. Momentum Research, Inc Durham NC

3. Université Paris Cité, INSERM UMR‐S 942 (MASCOT) Paris France

4. National Heart Centre Singapore Singapore

5. Duke–National University of Singapore Singapore

6. Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health University of Brescia Brescia Italy

7. Institute of Heart Diseases, Wroclaw Medical University Wrocław Poland

8. Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine University of California San Francisco San Francisco CA

9. Department of Anesthesiology and Critical Care and Burn Unit Saint‐Louis and Lariboisière Hospitals, FHU PROMICE, DMU Parabol, APHP Nord Paris France

Abstract

ABSTRACT Acute heart failure is a common and increasingly prevalent condition, affecting >10 million people annually. For those patients who survive to discharge, early readmissions and death rates are >30% everywhere on the planet, making it a malignant condition. Beyond these adverse outcomes, it represents one of the largest drivers of health care costs globally. Studies in the past 2 years have demonstrated that we can induce remissions in this malignant process if therapy is instituted rapidly, at the first acute heart failure episode, using full doses of all available effective medications. Multiple studies have demonstrated that this goal can be achieved safely and effectively. Now the urgent call is for all stakeholders, patients, physicians, payers, politicians, and the public at large to come together to address the gaps in implementation and enable health care providers to induce durable remissions in patients with acute heart failure.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3